Article
Dermatology
Jo Lambert, Jes Birger Hansen, Anne Sohrt, Luis Puig
Summary: This study compared the effects of brodalumab and ustekinumab on HRQoL in patients with moderate-to-severe plaque psoriasis over 52 weeks. The results showed that brodalumab treatment group had significantly greater improvement in DLQI scores compared to the ustekinumab group. More patients treated with brodalumab achieved a DLQI score of 0, indicating better quality of life.
DERMATOLOGY AND THERAPY
(2021)
Article
Medicine, General & Internal
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, Paolo Dapavo, Gabriella Fabbrocini, Paolo Gisondi, Giuseppe Micali, Anna Maria Offidani, Giovanni Pellacani, Nevena Skroza, Rosa Giuseppa Angileri, Martina Burlando, Anna Campanati, Carlo Giovanni Carrera, Andrea Chiricozzi, Andrea Conti, Clara De Simone, Vito Di Lernia, Enzo Errichetti, Marco Galluzzo, Claudio Guarneri, Claudia Lasagni, Serena Lembo, Francesco Loconsole, Matteo Megna, Maria Letizia Musumeci, Francesca Prignano, Antonio Giovanni Richetta, Emanuele Trovato, Marina Venturini, Ketty Peris, Piergiacomo Calzavara Pinton
Summary: A Delphi consensus document was developed to establish agreement on the use of brodalumab in the treatment of moderate-to-severe psoriasis. Consensus was reached on the key indications for the use of brodalumab based on the opinions of a panel of Italian dermatologists.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Xing Wang, Hannah Kaiser, Amanda Kvist-Hansen, Benjamin D. McCauley, Lone Skov, Peter Riis Hansen, Christine Becker
Summary: Psoriasis is linked to atherosclerotic cardiovascular disease. Systemically well-treated patients with psoriasis have lower levels of IL-17 pathway proteins. In patients without CVD, IL-17 correlates with disease severity and psoriasis. In patients with CVD, the correlation between IL-17 and disease severity is reduced.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Jose-Francisco Rocha, Ana Santos, Helena Gama, Paul Moser, Amilcar Falcao, Peter Pressman, A. Wallace Hayes, Patricio Soares-da-Silva
Summary: This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of BIA 10-2474. BIA 10-2474 was well tolerated at certain doses but could cause central nervous system adverse events at higher repeated doses.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Dermatology
M. C. Fargnoli, M. Esposito, P. Dapavo, A. Parodi, M. Rossi, R. Tiberio, S. Dastoli, A. M. Offidani, G. Argenziano, P. Gisondi, A. Lo Schiavo, F. Loconsole, P. Pella, F. Bardazzi, F. Cusano, M. Gattoni, M. Nacca, S. P. Cannavo, C. Pellegrini, A. Costanzo
Summary: This study evaluated the effectiveness and safety of brodalumab in treating moderate-to-severe plaque-type psoriasis in a real-world setting. Results showed that brodalumab led to a rapid and significant reduction in PASI score after 4 weeks of treatment, with continuous improvement in quality of life and patient satisfaction. The drug was effective even in patients with prior failure to anti-IL17 therapies.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Dermatology
Seong Jun Seo, Bong Seok Shin, Joo-Heung Lee, Haeyoun Jeong
Summary: The study demonstrates that brodalumab provides rapid and significant clinical benefit and is well tolerated in patients with moderate to severe plaque psoriasis in Korea. It can significantly improve disease severity assessment and the quality of life of dermatology patients.
JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Masaru Honma, Yasumasa Kanai, Kenta Murotani, Kei Ito, Chika Ohata, Fumikazu Yamazaki, Hidehisa Saeki, Mariko Seishima, Yoko Mizutani, Hiroki Kitabayashi, Shinichi Imafuku
Summary: This study assessed the effectiveness of brodalumab treatment on itching and skin pain in Japanese patients with psoriasis. The results showed that brodalumab treatment significantly improved itching and skin pain symptoms.
JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Congjun Jiang, Huan Zhou, Wanlu Zhang, Yu Xia, Baiyong Li, Xiang Ni, Guoqin Wang, Wenhui Zhang, Benchao Chen, Zhimei He, Min Zhang, Rui Chen, Hongzhong Jin, Liehua Deng
Summary: This study aimed to evaluate the safety, tolerability, immunogenicity, and induced expression of skin biomarkers of AK111 injection after multiple administrations in subjects with moderate-to-severe plaque psoriasis. The results showed that AK111 demonstrated encouraging preliminary efficacy, with increased proportions of subjects achieving desired clinical outcomes. AK111 was generally well-tolerated and safe, with no treatment-emergent anti-drug antibodies detected.
DERMATOLOGY AND THERAPY
(2023)
Article
Dermatology
Sara Cacciapuoti, Luca Potestio, Gianluca Guerrasio, Gabriella Fabbrocini, Massimiliano Scalvenzi, Angelo Ruggiero, Giuseppina Caiazzo, Matteo Megna
Summary: Brodalumab is effective and safe for the treatment of psoriasis in difficult-to-treat areas. Its use reduces the levels of inflammatory biomarkers, thus reducing systemic inflammation.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2023)
Article
Dermatology
K. Reich, L. Iversen, L. Puig, J. Lambert, U. Mrowietz, K. Kaplan Saday, R. B. Warren
Summary: Treatment with brodalumab resulted in sustained high levels of skin clearance in patients with moderate-to-severe psoriasis, with a high proportion of patients achieving PASI 90 at Week 120. The treatment was well tolerated and had a similar safety profile to previous studies, supporting its long-term efficacy and safety.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Dermatology
H. Hamm, D. Wilsmann-Theis, A. Tsianakas, T. Gambichler, K. Taipale, J. Lauterbach, U. Freudensprung, C. Makepeace
Summary: This study demonstrated that fumaric acid esters (FAE) showed superior treatment response compared to placebo in children and adolescents aged 10-17 with moderate-to-severe psoriasis after 20 weeks, with generally good tolerability. However, further studies are needed to confirm these findings.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Article
Immunology
Ying Li, Tao Ding, Jing Chen, Jinjun Ji, Weijie Wang, Bin Ding, Weihong Ge, Yongsheng Fan, Li Xu
Summary: Lupus nephritis, the most severe manifestation of systemic lupus erythematosus, is commonly treated with glucocorticoids. However, this treatment can lead to drug resistance and adverse effects in the long term. Combining glucocorticoids with traditional Chinese medical prescriptions, such as Hedyotis diffusa Willd, can attenuate the adverse effects and improve therapeutic efficiency. The study identified the chemical compounds in Hedyotis diffusa Willd extract, and found that the IL-17 signaling pathway was highly enriched. The combination treatment with Hedyotis diffusa Willd improved the blood parameters and reduced kidney inflammation in a mouse model of lupus nephritis.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Dermatology
K. B. Gordon, M. Lebwohl, K. A. Papp, H. Bachelez, J. J. Wu, R. G. Langley, A. Blauvelt, B. Kaplan, M. Shah, Y. Zhao, R. Sinvhal, K. Reich
Summary: The study found that Risankizumab demonstrated a favorable safety profile in patients with moderate-to-severe plaque psoriasis over both short-term and long-term treatment periods, with no increase in adverse event rates with long-term treatment.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Cell Biology
Koshiro Sonomoto, Rui Song, Daniel Eriksson, Anne M. Hahn, Xianyi Meng, Pang Lyu, Shan Cao, Ning Liu, R. Verena Taudte, Stefan Wirtz, Yoshiya Tanaka, Thomas H. Winkler, Georg Schett, Didier Soulat, Aline Bozec
Summary: This study found that only dietary fat, not carbohydrates or proteins, exacerbates psoriatic disease. High-fat diet can change the intestinal mucus layer and microbiota composition, leading to the aggravation of psoriatic skin inflammation. Changing the intestinal microbiota can effectively block the skin inflammation caused by high-fat diet, inhibit the systemic interleukin-17 (IL-17) response, and increase the population of mucophilic bacteria Akkermansia muciniphila. Oral administration of live or heat-killed A. muciniphila can effectively inhibit the enhancement of psoriatic disease caused by high-fat diet.
Article
Chemistry, Medicinal
Junjun Ling, Liang Zhang, Yan Wang, Aoshuang Chang, Yi Huang, Houyu Zhao, Xianlu Zhuo
Summary: This study found that fisetin, a dietary flavonoid, can reverse chemoresistance and increase the sensitivity of head and neck cancer cells to cisplatin (DDP). Through network pharmacology analysis, 32 genes were identified as common targets of fisetin and DDP-resistance, including HSP90AA1, PPIA, and PTPRS. Molecular docking experiments confirmed the strong binding between fisetin and these candidate proteins. Fisetin increased DDP sensitivity by downregulating HSP90AA1 and IL-17. This study highlights the potential of fisetin as a therapeutic agent for reversing DDP-resistance in head and neck cancer cells.
PHYTOTHERAPY RESEARCH
(2023)
